Immunotherapy plus chemo and radiation shows promise for rare thymic cancer
NCT ID NCT07479628
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests whether combining the immunotherapy drug adebrelimab with chemotherapy and radiation before surgery can help shrink tumors in people with locally advanced thymic carcinoma. About 31 participants will receive the treatment, then have surgery if the tumor becomes removable. After surgery, they'll get more chemotherapy, radiation, and up to a year of adebrelimab. The study aims to see how well the tumor responds and whether the treatment is safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Adebrelimab (an immunotherapy drug) plus chemotherapy (albumin-bound paclitaxel and cisplatin) and radiation therapy
- What this could lead to
- If successful, this combination could shrink tumors enough to allow surgery and improve long-term control of thymic carcinoma.
- What could go wrong
- This is a small, early-phase trial with only 31 participants, so results may not apply to everyone. The combination of immunotherapy, chemotherapy, and radiation can cause significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYMIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Shorter radiation after thymic tumor surgery may cut side effects
- Fewer radiation sessions may be just as effective for thymic tumors after surgery
- Immune cells engineered to hunt thymus cancer show promise in early trial
- Immunotherapy drug nivolumab tested for rare thymus cancers
- New combo therapy shows promise for rare chest cancer
- New trial aims to stop thymic cancer return with Chemo-Radiation combo